Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LME Subtype-Guided Precision Combination Therapy in B-Cell Lymphoma After CAR-T Failure
NCT07602322Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Progression-Free Survival at 24 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07602322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602322.